BioMEMS and Biomedical Nanotechnology [electronic resource] : Volume IV: Biomolecular Sensing, Processing and Analysis / edited by Mauro Ferrari, Rashid Bashir, Steve Wereley.Material type: TextLanguage: English Publisher: Boston, MA : Springer US, 2007Description: XXII, 410 p. online resourceContent type: text Media type: computer Carrier type: online resourceISBN: 9780387258454Subject(s): Engineering | Medicine | Biotechnology | Biomedical engineering | Nanotechnology | Engineering | Biomedical Engineering | Biophysics/Biomedical Physics | Nanotechnology | Biomedicine general | BiotechnologyAdditional physical formats: Printed edition:: No titleDDC classification: 610.28 LOC classification: R856-857Online resources: Click here to access online
Micro and Nanoscale Biosensors and Materials -- Biosensors and Biochips -- Cantilever Arrays: A Universal Platform for Multiplexed Label-Free Bioassays -- An On-Chip Artificial Pore for Molecular Sensing -- Cell Based Sensing Technologies -- 5 Fabrication Issues of Biomedical Micro Devices -- Intelligent Polymeric Networks in Biomolecular Sensing -- Processing and Integrated Systems -- A Multi-Functional Micro Total Analysis System (?TAS) Platform for Transport and Sensing of Biological Fluids using Microchannel Parallel Electrodes -- Dielectrophoretic Traps for Cell Manipulation -- BioMEMS for Cellular Manipulation and Analysis -- Implantable Wireless Microsystems -- Microfluidic Tectonics -- AC Electrokinetic Stirring and Focusing of Nanoparticles -- Micro-fluidics and Characterization -- Particle Dynamics in a Dielectrophoretic Microdevice -- Microscale Flow and Transport Simulation for Electrokinetic and Lab-on-Chip Applications -- Modeling Electroosmotic Flow in Nanochannels -- Nano-Particle Image Velocimetry: A Near-Wall Velocimetry Technique with Submicron Spatial Resolution  -- Optical MEMS-Based Sensor Development with Applications to Microfluidics -- Vascular Cell Responses to Fluid Shear Stress.
Less than twenty years ago photolithography and medicine were total strangers to one another. They had not yet met, and not even looking each other up in the classi?eds. And then, nucleic acid chips, micro?uidics and microarrays entered the scene, and rapidly these strangers became indispensable partners in biomedicine. Asrecentlyastenyearsagothenotionofapplyingnanotechnologytothe?ghtagainstd- ease was dominantly the province of the ?ction writers. Thoughts of nanoparticle-vehicled deliveryoftherapeuticalstodiseasedsiteswereanexerciseinscienti?csolitude,andgrounds for questioning one’s ability to think “like an established scientist”. And today we have nanoparticulate paclitaxel as the prime option against metastatic breast cancer, proteomic pro?lingdiagnostictoolsbasedontargetsurfacenanotexturing,nanoparticlecontrastagents for all radiological modalities, nanotechnologies embedded in high-distribution laboratory equipment, and no less than 152 novel nanomedical entities in the regulatory pipeline in the US alone. Thisisatransformingimpact,byanymeasure,withclearevidenceoffurtheracceleration, supported by very vigorous investments by the public and private sectors throughout the world. Even joining the dots in a most conservative, linear fashion, it is easy to envision scenarios of personalized medicine such as the following: patient-speci?c prevention supplanting gross, faceless intervention strategies; early detection protocols identifying signs of developing disease at the time when the disease is most easily subdued; personally tailored intervention strategies that are so routinely and inexpensively realized, that access to them can be secured by everyone; technologies allowing for long lives in the company of disease, as good neighbors, without impairment of the quality of life itself.